NCT02129036

Brief Summary

Clear cell carcinoma comprises 5-10% of surface epithelial ovarian cancers, and about 30-40% of the patients with clear cell carcinoma are diagnosed in the advanced stage. The investigators studied the response to chemotherapy and survival for either paclitaxel-platinum based chemotherapy or conventional platinum-based chemotherapy among all stages clear cell ovarian carcinoma. Prognostic factors for survival among the patients with pure, advanced, clear cell ovarian carcinoma were also evaluated.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
5

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Apr 2008

Longer than P75 for all trials

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2008

Completed
9 months until next milestone

First Submitted

Initial submission to the registry

January 4, 2009

Completed
3.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2012

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2013

Completed
5 months until next milestone

First Posted

Study publicly available on registry

May 2, 2014

Completed
Last Updated

August 9, 2019

Status Verified

April 1, 2014

Enrollment Period

4.7 years

First QC Date

January 4, 2009

Last Update Submit

August 7, 2019

Conditions

Ovarian Cysts

Keywords

Ovarian cancerClear cell carcinomaPaclitaxel-platinumChemotherapyresponse to chemotherapysurvival of clear cell ovarian carcinomaPrognostic factors

Outcome Measures

Primary Outcomes (1)

  • Overall survival (OS)

    Overall survival (up to 6 years)

Eligibility Criteria

Age30 Years - 70 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

total 300 patients of ovarian clear cell carcinoma post operation from 8 institution.

You may qualify if:

  • Clinical diagnosis of Ovarian clear cell carcinoma

You may not qualify if:

  • not undergo operation

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Ovarian CystsOvarian NeoplasmsAdenocarcinoma, Clear Cell

Condition Hierarchy (Ancestors)

CystsNeoplasmsOvarian DiseasesAdnexal DiseasesGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital DiseasesGonadal DisordersEndocrine System DiseasesEndocrine Gland NeoplasmsNeoplasms by SiteGenital Neoplasms, FemaleUrogenital NeoplasmsAdenocarcinomaCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic Type

Study Officials

  • Chih-Ming Ho

    Gynecologic Cancer Center, Cathay general Hospital

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Dr

Study Record Dates

First Submitted

January 4, 2009

First Posted

May 2, 2014

Study Start

April 1, 2008

Primary Completion

December 1, 2012

Study Completion

December 1, 2013

Last Updated

August 9, 2019

Record last verified: 2014-04